Sheet 1 of 3

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 3151

APPLICATION NO.: 10/668,067

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

INVENTOR: Manning, et al.

Filed: 9/22/2003

Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	. Subclass	Filing Date If Appropriate
You	1	5684008	11/4/97	Hallinan	31	41	11/9/94
Yn-	2	5629322	5/13/97	Guthikonda	31	47	6/6/95

FOREIGN PATENT DOCUMENTS

Examiner							Transla	ition
Initial		Document Number	Date	Country	Class	Subclass	Yes	No
Yn-	3	93/13055	7/8/93	PCT			†	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial of citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 COMMERCE, PATENT AT	U.S. DEPARTMENT OF ND TRADEMARK OFFICE	NO.: 3151/1	APPLICATION NO.: 10/668,067		
INFORMATION STATEMENT E	N DISCLOSURE BY APPLICANT	INVENTOR: Manning, et al.			
(Use several she	ets if necessary)	Filed: 9/22/2003	Group:		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C		I (merading realist, Date, Fertillent Lages, Etc.)
Examiner Initial		
mitiai	ļ	
4	4	N. McCartney-Francis, 1993, Suppression of Arthritis by an inhibitor of nitric oxide
In	Ţ	synthase, The Journal of experimental medicine.178: 749-754
	5	A.R. Amin, 1995, The expression and regulation of nitric oxide synthase in human
_		osteoarthritis-affected chondrocytes: evidence for an inducible "neuronal-like" nitric oxide
/		synthase. J. Exp. Med. 182:2097-2102
	6	Pelletier, J. P., J. Martel-Palletier, and D.S. Howell. 1997. Etiopathogenesis of
1		osteoarthritis. In Arthritis and Allied Conditions. A Textbook of Rheumatology. W. J.
/n		Koopman, editor, Williams & Wilkins, Baltimore. 1969-1984
	7	Dean, D. D. 1991. Proteinase-mediated cartilage degradtion in osteoarthritis.[Review].
The	 	Semin. Arthritis Rheum. 20:2-11
	8	Dore, S., J. P. Pelletier, J. A. DiBattista, G. Tardif, P. Brazeau, and J. Martel-Pelletier. 1994.
,		Human osteoarthritic chondrocytes possess an increased number of insulin-like growth
411		factor 1 binding sites but are unresponsive to its stimulaton. Possible role of IGF-1-Binding
Jul		Proteins. Arthritis Rheum. 37:253-263
	9	
l	,	Hickery, M. S., R. M. J. Palmer, I. G. Charles, S. Moncada, and M. T. Bayliss. 1994. The
JA-		role of nitric oxide in IL-1 and TNFa-induced inhibition of proteoglean synthesis in human
<i>U</i>		articular cartilage. Trans Orthop Res Soc 19:77.(Abstr.)
,	10	Taskiran, D., M. Stefanovic-Racic, H. Georgescu, and C. Evans. 1994. Natric oxide meiates
Jm	ļ	suppression of cartilage proteglycan synthesis by interleukin-1. Biochem.Biophys. Res
0 477		Commun. 200:142-148
	11	Jarvinen, T. A. H., T. Moilanen, T. L. N. Jarvinen, and E. Moilanen. 1995. Nitric oxide
<i>ي</i> ر	/	mediates interleukin-1 induced inhibition of glycosaminogylcan synthesis in rat articular
Jun	İ	cartilage. Mediators of Inflamation 4:107-111
^	12	Stadler, J., M. Stefanovic-Racic, T. R. Billiar, R.D. Curran, L. A. McIntyre, H. I. Georgescu,
Pus/		R. L. Simmons, and C.H. Evans. 1991. Articular chondrocytes synthesize nitric oxide in
fur		response to cytokines and lipopolysaccharide. J. Immunol, 147:3917-3920
	13	Palmer, R. M. J., M. S. Hickery, I. G. Charles, S. Moncada, and M.T. Bayliss. 1993.
An w		Induction of nitric oxide synthase in human chondrocytes. Biochem. Biophys. Res.
Um		Commun. 193:398-405
	14	
	14	I. G. Charles, R. M. Palmer, M. S. Hickery, M. T. Bayliss, A. P. Chubb, V. S. Hall, D. W.
φ		Moss and S. Moncada. 1993. Cloning, charaterization and expression of a cDNA ecoding
d me		and inducible nitric oxide synthase from the human chondrocyte. Proc. Natl. Acad. Sci.
V	L	USA. 90:11419-11423
	15	Pelletier, J. P., F. Mineau, P. Ranger, G. Tardif, and J. Martel-Pelletier. 1996. The increased
		synthesis of inducible nitric oxide inhibits IL-IRa synthesis by human articular
7m4		chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage
1 /		4:77-84

		_
	16	I. B. McInnes, B. P. Leung, M. Field, X. Q. Wei, F. –P. Huang, R. D. Sturrock, A.
Þ		Kinninmonth, J. Weidner, R. Mumford and F. Y. Leiw. 1996. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J. Exp. Med. 184:1519-
1-		1524
	17	Farrell, A. J., D. R. Blake, R. M. Palmer, and S. Moncada. 1992 Increased concertration of
4xC		nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in
) , ,	<u> </u>	rheumatic diseases. Ann Rheum. Dis. 51:1219-1222
	18	Sakuri, H., H. Kohsaka, M. Liu, H. Higasshiyama, Y. Hirata, K. Kanno, I. Saito, and N.
Har		Miyasaka. 1995. Nitric Oxide production and inducible nitric oxide synthase expression in
<i>)</i> - C	19	inflammatory arthritis. J. Clin. Invest. 96:2357-2363
\mathcal{L}	19	Cannon, G. W., S. J. Openshaw, J. B. Hibbs, Jr., J. R. Hoidal, T. P. Huecksteadt, and M.M. Griffiths. 1996. Nitric oxide production during adjuvant-induced and collagen-induced
Jun		arthritis. Arthritis Rheum. 39:1677-1684
1	20	Evans, C.H., M. Stefanovic-Racic, and J. Lancaster. 1995. Nitric oxide and its role in
J~		orthopaedic disease. Clin Orthop 312:275-294
1	21	Stefanovic-Racic, M., J. Stadler, and C. H. Evans. 1933. Nitric oxide and arthritis. Arthritis
/~~	<u> </u>	Rheum. 36:1036-1044
P	22	Murrell, G. G. C., D. Jang, and R. J. Williams. 1995. Nitric oxide activites metalloprotease
<u>/~</u>		enzymes in articular cartilage. Bioochem Biophys Res Commun 206:15-21
	23	Connor, J.R., P. T. Manning, S. L. Settle, W. M. Moore, G. M. Jerome, R. K. Webber, F. S.
フヘー	_	Tjoeng, and M. G. currie. 1995. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 273:15-24
	24	Stefanovic-Racic, M., K. Meyers, C. Meschter, J.W. Coffey, R. A. Hoffman, and C. H.
1	27	Evans. 1994. N-monomethy arginine, an inhibitor of nitric oxide synthase, suppresses the
		development of adjuvant arthritis in rats. Arthritis Rheum. 37:1062-1069
	25	Stefanovic-Racic, M., K. Meyers, C. Meschter, J. W. Coffey, R. A. Hoffman, and C. H.
\mathcal{A}		Evans. 1995. Comparison of the nitric oxide synthase inhibitors methylarginine and
"hu		aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. J.
/	26	Rheumatol. 22:1922-1928
0	26	Moore, W. M., R. K. Webber, G. M. Jerome, F. S. Tjoeng, T. P. Misko, and M. G. Currie. 1994. L-N6-(1 – Iminoethyl) lysine: a selective inhibitor of inducible nitric oxide synthase.
/ ~ ~		J Med Chem 37:3886-3888
	27	Maier, R., G. Bible, J. Rediske, and M. Lotz. 1994. Inducible nitric oxide synthase from
4		human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochim.
m		Biophys. Acta 145:1208 (Abstr.)
-1	28	Pelletier, J. P., J. A. DiBattista, J. P. Raynauld, S. Wilhelm, and J. Martel-Pelletier. 1995.
9.		The in vivo effects of intraarticular corticosteriod injections on cartilage lesions,
		stromelysin, iterleukin-1 and oncogene protein synthesis in experimental osteoarthritis. Lab. Invest. 72:578-586
	29	Pelletier, J. P., F. Mineau, J. P. Raynauld, J. F. Jr. Woessner, Z. Gunja-Smith, and J.
	23	Martel-Pelletier. 1994. Inraarticular injections with methylprednisolone acetate reduce
4		osteoarthritis lesions in Parallel with chondrocyte stormelysin syntheis in experimental
		osteoarthritis. Arthitis Rheum. 37:414-423
	30	Fernandes, J. C., J. Martel-Pelletier, I. G. Otterness, A. Lopez-Anaya, F. Mineau, G. Tardif,
4/2		and J. P. Pelletier. 1995. Effectes of tenidap on caine experimental osteoarthritis: I.
/		Morphologic and metalloprotease anslysis. Arthritis Rheum. 38:1290-1303
ار	31	Mankin, H. J., H. Dorfman, L. Lippiello, and A. Zarins. 1971. Biochemical and metabolic
Jhu		abnormalities in articular cartilage from osteoarthritis human hips. II. Correlation of
	32	morphology with biochemical and metabolic data. J. Bone Joint Surg. Am. 53:523-537 Cawson, T. E. and A. J. Barrett. 1979. A rapid and reproducible assay for collagenase using
\mathcal{L}	J2	[1 – 14C] acetylated collagen. Anal. Biochem. 99:340-345
<i></i>		11

•

The	33	Chavira, R. Jr., T. J. Burnett and J. H. Hageman. 1984. Assaying proteinases with azocoll. Anal. Biochem. 136:446-450
You	34	Brandt, K. D. 1994. Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog. An animal model of osteoarthritis. [Review]. Ann. NY Acad. Sci. 732:199-205
9	35	Caron, J. P., J. C. Fernandes, J. Martel-Pelletier, G. Tardif, F. Mineau, C. Geng, and J. P. Pelletier. 1996. Chondroprtective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum. 39:1535-1544
In	36	Van Beuningen, H. M., P. M. Van der Kraan, O. J. Arntz, and W. B. van den Berg. 1994. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab. Invest. 71:279-290
Ym	J ³⁷	Blanco, F. J., R. L. Ochs, H. Schwarz and M. Lotz. 1995. Chondrocyte apoptsis induced by nitric oxide. Am. J. Pathol. 146:75-85
The	38	Beckman, J. S. and Koppenol. 1996. Nitric oxide, superoxide and peroxynitrite: the good, the bad, and the ugly. Am. J. Physiol. 271:C1424-C1437
Jn -	39	Salvemini, D., P. T. Manning, B. S. Zweifel, K. Siebert, J. Connor, M. G. Curri, P. Needleman, and J. L. Masferrer. 1995. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflamitory properties of nitric oxide synthase inhibitors. J. Clin. Invest. 96:301-308
Ju	40	Salvemini, D., Z. –Q. Wang, P. S. Wyatt, D.M. Bourdon, M. H. Marino, P. T. Manning, and M. G. Currie. 1996. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 118:829-838

EXAMINER /	/		DATE CONSID	ERED
	<i>l</i>		Divisi Consid	percey.
	-flur	-	(2)//	3/14
				-//-/- -/-

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)